UCL shares insights to advance translational success at Joint BRC & UKCRF Network Conference

UCL ranks second in the UK for research power and hosts over 1,800 biomedical research groups — a distinction that’s no coincidence, but the result of key strengths that set us apart.

On 14 and 15 July,  Jane Kinghorn (Director) and Pamela Tranter (Head of the Translational Research Group) from the UCL Translational Research Office (TRO) attended the Joint BRC and UKCRF Network Conference in Birmingham. They led an interactive workshop with around 30 research colleagues from across the UK’s biomedical research ecosystem, sharing UCL’s experience and best practice in driving translational success. 

Some of UCL's translational success factors at a glance:

• Extensive biomedical infrastructure
  We partner with nine hospitals and three Biomedical Research Centres (BRCs), with joint academic-clinical appointments that accelerate translation.
• Comprehensive translational support
  The UCL Translational Research Office supports a wide range of therapeutic areas, helping secure funding and build partnerships that deliver clinical and commercial impact.
• A leading product pipeline
  We provide proof-of-concept funding for early to mid-stage research, de-risking projects and maximising their potential.
• A diverse translational culture and talent pipeline
  Through the UCL Therapeutic Innovation Networks, we support early career researchers with training, knowledge exchange and exposure — nurturing the next generation of translational leaders.

Enquiries

If you are a UCL researcher looking for translational research consultation or funding application support, please contact: Dr Pamela Tranter, p.tranter@ucl.ac.uk

If you are an industry partner looking for collaboration opportunities with UCL, please contact: Dr Carmel Reilly, carmel.reilly@ucl.ac.uk

Links

• UCL Therapeutic Innovation Networks (TINs)
• Translational Research – Funding opportunities
• UCL cemented as global leader in developing and trialling advanced medicinal therapies
• Success from lab to market 2025: Introducing one of the world's largest development pipelines for Advanced Therapy Medicinal Products (ATMP)

Interested to stay informed of upcoming news, events and funding calls?

• Subscribe to our newsletter and you would automatically become a member of UCL TINs (Therapeutic Innovation Networks) and be the first to receive our event invitations

• Follow us on social media (LinkedIn, Bluesky, X) and stay tuned to our news and updates.